Home/Filings/4/0000950170-25-032725
4//SEC Filing

Mokari Atabak 4

Accession 0000950170-25-032725

CIK 0001088856other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 7:34 PM ET

Size

11.7 KB

Accession

0000950170-25-032725

Insider Transaction Report

Form 4
Period: 2025-02-28
Mokari Atabak
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2025-03-03$59.07/sh+232$13,70412,802 total
  • Tax Payment

    Common Stock

    2025-03-03$60.58/sh228$13,81212,570 total
  • Award

    Stock option (right to buy)

    2025-02-28+140,000140,000 total
    Exercise: $60.58Exp: 2035-02-28Common Stock (140,000 underlying)
  • Award

    Common Stock

    2025-03-03+23213,034 total
Footnotes (7)
  • [F1]These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  • [F2]The closing price on February 28, 2025 was used to calculate the withholding obligation.
  • [F3]Includes 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  • [F4]The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025.
  • [F5]In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  • [F6]Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  • [F7]Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

Issuer

CORCEPT THERAPEUTICS INC

CIK 0001088856

Entity typeother

Related Parties

1
  • filerCIK 0001678419

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 7:34 PM ET
Size
11.7 KB